Flow cytometry measurements revealed that the proportions of CD25+ or CD69+ activated CD8+ T cells and CD107a+ cytotoxic subgroups were upregulated (P = 0.0130; P = 0.0627; P = 0.0260) (Fig. 5H), corroborating the improvement of T cell-based adaptive anti-tumor immunity. The gene discussed is LAMP1; the disease is neoplasm.